(Total Views: 253)
Posted On: 07/13/2017 4:39:26 PM
Post# of 72447
SA has an actual news story that briefly summarizes the presentation, without Mako-influenced garbage:
Quote:
Innovation Pharmaceuticals (OTCQB:IPIX) announces positive results from a 17-subject open-label proof-of-concept clinical trial assessing antibiotic Brilacidin in patients with mild-to-moderate ulcerative proctitis/ulcerative proctosigmoiditis, two forms of inflammatory bowel disease (IBD). The results were presented today at the Drug Discovery & Therapy World Congress in Boston.
In 15 evaluable patients in three arms, 67% (n=10/15) achieved clinical remission after six weeks of treatment.
On the safety front, Brilacidin was generally well-tolerated with no serious adverse events observed.
The company intends to advance the product into the next stage of development.
Brilacidin is a member of a new class of antibiotics called defensin-mimetics which are modeled after host defense proteins. These are the "front line" of defense in the human immune system. An oral rinse formulation is in Phase 2 development for the treatment of chemoradiation-associated oral mucositis.
(3)
(0)
